Department of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland; Neuroimmunological Unit, Polish Academy of Sciences, Poznan, Poland.
Division of Gynecological Surgery, Poznan University of Medical Sciences, Poznan, Poland.
Taiwan J Obstet Gynecol. 2014 Dec;53(4):490-3. doi: 10.1016/j.tjog.2013.08.009.
High levels of toxic reactive oxygen species have been found in many types of cancer cells. Serum arylesterase (ARE) and paraoxonase (PON) are esterase enzymes that have strong antioxidant characteristics. The main purpose of our study was to evaluate the activity of ARE and PON in the sera of patients with ovarian cancer and benign ovarian tumors.
This study included 30 patients with ovarian cancer, 42 patients with benign ovarian tumors, and 19 healthy age- and sex-matched individuals. ARE and PON activities were measured using spectrophotometry.
Serum ARE activity was significantly different among the three studied groups (p<0.0001). However, posthoc tests revealed that ARE activity was lower in the benign ovarian tumor group (median, 1.53 U/mL; range, 0.43-2.47 U/mL) than in the other groups. There were no differences in ARE activity between patients with ovarian cancer (1.89 U/mL; range, 1.01-2.56 U/mL) and healthy individuals (2.05 U/mL; range, 0.79-2.44 U/mL). We found no differences in PON activity or the PON:ARE activity ratio between the studied groups. Tumor size in the benign ovarian tumor group was positively correlated with ARE activity (R Spearman=0.46, p=0.003) and negatively correlated with PON activity (R Spearman=-0.50, p=0.001). The ARE and PON activities were not influenced by histological type, ovarian cancer grade, or disease advancement.
ARE activity is higher in patients with ovarian cancer than in patients with benign ovarian tumors; however, the serum activity of ARE is similar between patients with cancer and healthy individuals.
在许多类型的癌细胞中发现了高水平的有毒活性氧。血清芳基酯酶(ARE)和对氧磷酶(PON)是具有强大抗氧化特性的酯酶。我们研究的主要目的是评估卵巢癌和良性卵巢肿瘤患者血清中 ARE 和 PON 的活性。
本研究包括 30 例卵巢癌患者、42 例良性卵巢肿瘤患者和 19 例年龄和性别匹配的健康个体。使用分光光度法测定 ARE 和 PON 活性。
三组研究对象的血清 ARE 活性存在显著差异(p<0.0001)。然而,事后检验显示良性卵巢肿瘤组(中位数,1.53 U/mL;范围,0.43-2.47 U/mL)的 ARE 活性较低。卵巢癌患者(1.89 U/mL;范围,1.01-2.56 U/mL)和健康个体(2.05 U/mL;范围,0.79-2.44 U/mL)的 ARE 活性无差异。研究组之间 PON 活性或 PON:ARE 活性比无差异。良性卵巢肿瘤组的肿瘤大小与 ARE 活性呈正相关(R Spearman=0.46,p=0.003),与 PON 活性呈负相关(R Spearman=-0.50,p=0.001)。ARE 和 PON 活性不受组织学类型、卵巢癌分级或疾病进展的影响。
卵巢癌患者的 ARE 活性高于良性卵巢肿瘤患者;然而,癌症患者和健康个体的血清 ARE 活性相似。